Cargando…

Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis

While death receptor ligands (Fas and TRAIL) kill chemoresistant tumor cell lines, related therapies have limited clinical efficacy as single agents. Death receptor signaling is modulated by nuclear factor-κB (NFκB), a family of transcription factors which are constitutively active in B-cell maligna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paiva, Cody, Claire Godbersen, J., Rowland, Taylor, Danilova, Olga V., Danes, Christopher, Berger, Allison, Danilov, Alexey V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400571/ https://www.ncbi.nlm.nih.gov/pubmed/28177892 http://dx.doi.org/10.18632/oncotarget.15050

Ejemplares similares

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
por: Torka, Pallawi, et al.
Publicado: (2023)

NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells
por: Kittai, Adam S., et al.
Publicado: (2021)

Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells
por: Wang, Xiaofang, et al.
Publicado: (2016)

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia
por: Paiva, Cody, et al.
Publicado: (2017)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

The Nedd8‐activating enzyme inhibitor MLN4924 (TAK‐924/Pevonedistat) induces apoptosis via c‐Myc‐Noxa axis in head and neck squamous cell carcinoma
por: Zhang, Wenjuan, et al.
Publicado: (2018)

Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
por: Ishikawa, Y, et al.
Publicado: (2017)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
por: Bhatia, Shailender, et al.
Publicado: (2016)

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
por: Swords, R T, et al.
Publicado: (2017)

Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells
por: Paiva, Cody, et al.
Publicado: (2015)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2020)

Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
por: Ishikawa, Y., et al.
Publicado: (2019)

Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia
por: Wang, Xiaoguang, et al.
Publicado: (2023)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
por: Ferris, Jennifer, et al.
Publicado: (2020)

ABCG2 Overexpression Contributes to Pevonedistat Resistance
por: Kathawala, Rishil J., et al.
Publicado: (2020)

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016)

Expression of NEDD9 and connexin-43 in neoplastic and stromal cells of gastric adenocarcinoma
por: Lerotić, Ivan, et al.
Publicado: (2021)

Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents
por: Paiva, C, et al.
Publicado: (2015)

Nedd8 processing enzymes in Schizosaccharomyces pombe
por: O’Donoghue, Jean E, et al.
Publicado: (2013)

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
por: Faessel, Hélène, et al.
Publicado: (2019)

Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway
por: Xu, Junfeng, et al.
Publicado: (2022)

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies
por: Faessel, Hélène M., et al.
Publicado: (2019)

A Metal-Based Inhibitor of NEDD8-Activating Enzyme
por: Zhong, Hai-Jing, et al.
Publicado: (2012)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia
por: Han, Kun, et al.
Publicado: (2016)

Pevonedistat Inhibits SOX2 Expression and Sphere Formation but Also Drives the Induction of Terminal Differentiation Markers and Apoptosis within Arsenite-Transformed Urothelial Cells
por: Mehus, Aaron A., et al.
Publicado: (2023)

Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes
por: Hjerpe, Roland, et al.
Publicado: (2012)

Profiling the Cross Reactivity of Ubiquitin with the Nedd8 Activating Enzyme by Phage Display
por: Zhao, Bo, et al.
Publicado: (2013)

NEDD8-conjugating enzyme E2s: critical targets for cancer therapy
por: Zhou, Lisha, et al.
Publicado: (2023)

Inhibition of NEDD8 and FAT10 ligase activities through the degrading enzyme NEDD8 ultimate buster 1: A potential anticancer approach
por: Tan, Ka-Liong, et al.
Publicado: (2016)

Serine enzymes released by cultured neoplastic cells
Publicado: (1978)

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial
por: Zhou, Xiaofei, et al.
Publicado: (2021)

Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
por: Xu, G. Wei, et al.
Publicado: (2014)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
por: Cojocari, Dan, et al.
Publicado: (2021)

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
por: Kong, Tim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8rui6k85jm7cb7nfan4qjfdi5g